Cronos Group Reports 2026 First Quarter Results
Record profit and a fresh buyback cannot fully conceal a stalling European anchor acquisition.
The most recent release—Q1 2026 results on May 11, 2026—delivered a beat on multiple fronts. Net revenue hit a record $45.2 M (+40 % YoY), gross profit advanced 39 %, and net income more than doubled (+103 %) to $15.7 M. Adjusted EBITDA improved 122 % to $5.1 M. The Spinach® brand captured #1 vape market share in Canada and held #1 in edibles. International growth outside Israel jumped 97 % YoY. A new $50 M share‑buyback program was approved.
However, the same release pushed the closing of the CanAdelaar acquisition from June 9 to September 9 2026, citing Dutch regulatory clearance needs.
Earlier releases show a consistent cadence of product launches (Spinach STIX pre‑rolls, Spinach PUFFERZ AIO vape, Lord Jones Live Resin Fusions, Sourz multipacks) and the strategic expansion of the Lord Jones® brand into Israel. The CanAdelaar deal was unveiled in December 2025, with a ~$67 M upfront price and was originally slated for an H1 2026 close. The transcript from the FY 2025 call (February 2026) reiterated that timeline and flagged GrowCo‑related margin pressures that were expected to ease in 2026.
The Q1 2026 numbers are materially positive. A swing from a net loss in Q4 2025 to a $15.7 M profit, combined with record revenue and a big‑ticket buyback, signals accelerating operating momentum. The Spinach® market‑share gains (especially vapes) validate the innovation‑driven brand strategy. International revenue almost doubled, suggesting the “borderless products” thesis is gaining traction.
The CanAdelaar delay is a minor negative—management framed it as a regulatory process, not a deal risk—but it introduces uncertainty into the timeline and pushes a key catalyst out by a quarter. The transcript’s promise of an H1 2026 close is clearly missed, which erodes credibility slightly. Still, the fundamental quarter was strong enough to offset the delay’s weight. The buyback also shows confidence in the stock’s undervaluation.
Cronos Group is a Canadian‑domiciled global cannabis company with a portfolio spanning adult‑use in Canada (Spinach®, Lord Jones®), medical cannabis in Israel (PEACE NATURALS®, Lord Jones®), and an expanding international footprint (Germany, Australia, UK). The flagship project is the pending acquisition of CanAdelaar B.V., the largest operator in the Netherlands’ adult‑use pilot program, which would cement a #1 European market position and align with Cronos’ “borderless products” strategy. Domestically, the expansion of Cronos GrowCo (an in‑house cultivation JV) aims to supply both Canadian and international channels with high‑quality flower.